Although previous studies have established PELI1 as an oncogene in malignancies such as breast cancer, lung cancer, and lymphoma—primarily through its modulation of the PI3K/AKT and B-cell signaling pathways (32, 33)—our findings uncovered a previously uncharacterized role and mechanism for PELI1 in LIHC. This evidence concerns the gene AKT1 and breast cancer.